Copyright
©The Author(s) 2019.
World J Clin Cases. Oct 6, 2019; 7(19): 2995-3011
Published online Oct 6, 2019. doi: 10.12998/wjcc.v7.i19.2995
Published online Oct 6, 2019. doi: 10.12998/wjcc.v7.i19.2995
Table 1 Empirical therapeutic trials
Ref. | Design | EL | Characteristics | Outcomes | Treatment |
Hanson et al[8], 1995 | Pros Uncontr | IIIb | Suspected LPR (n = 141) | Symptom and sign resolution: 51% | 4 wk omeprazole (20 mg, 1/d) and diet |
Jaspersen et al[9], 1996 | Pros Uncontr | IIIb | Suspected LPR (n = 21) | Laryngeal sign improvement: 100% | 4 wk omeprazole (40 mg, 1/d) |
Shaw et al[10], 1997 | Pros Uncontr | IIIb | Suspected LPR (n = 96) | Pre to post-score improvement: + | 12 wk omeprazole (20 mg/d) |
Wo et al[11], 1997 | Pros Uncontr | IIIb | Suspected LPR (n = 21) | Pre to post-score improvement: + | 8 wk omeprazole (40 mg, 1/d) and diet |
Metz et al[12], 1997 | Pros Uncontr | IIIb | Suspected LPR (n = 10) | Symptom and sign resolution: 60% | 4 wk omeprazole (20 mg/d) |
Habermann et al[13], 1999 | Pros Uncontr | IIIb | Suspected LPR (n = 29) | Pre to post-score improvement: + | 6 wk pantoprazole (40 mg/d) |
Havas et al[14], 1999 | Placebo RCT | Ib | Gr1: suspected LPR (n = 7) | Pre to post-score improvement: + | Gr1-2: 12 wk placebo/lanzoprazole (30 mg 2/d) and Diet |
Gr2: suspected LPR (n = 8) | |||||
El-Serag et al[15], 2001 | Placebo RCT | Ib | Gr1: suspected LPR (n = 10) | 54% of symptom resolution | Gr1-2: 12 wk placebo/lansoprazole (30 mg 2/d) |
Gr2: suspected LPR (n = 10) | |||||
Langevin et al[16], 2001 | Placebo RCT | Ib | Gr1: suspected LPR (n = 14) | Pre to post-score improvement | Gr1-2: 12 wk placebo/omeprazole (40 mg/d) |
Gr2: suspected LPR (n = 16) | |||||
Hamdan et al[17], 2001 | Pros Uncontr | IIIb | Suspected LPR (n = 22) | Pre to post-score improvement: + | 4 wk pantoprazole (40 mg, 2/d), cisapride (20 mg, 2/d) and diet |
Rodríguez-Téllez et al[18], 2002 | Pros Uncontr | IIIb | Suspected LPR (n = 21) | Pre to post-score improvement: + | 12 wk omeprazole (20 mg, 2/d) |
Habermann et al[19], 2002 | Pros Uncontr | IIIb | Suspected LPR (n = 24) | Pre to post-score improvement: + | 6 wk pantoprazole (40 mg/d) |
DelGaudio et al[20], 2003 | Pros Uncontr | IIIb | Gr1: LPR responder (n = 19) | 50% symptom improvement: 63% | 8 wk esomeprazole (40 mg 1/d) and diet |
Bilgen et al[21], 2003 | Pros Contr | IIIb | Gr1: suspected LPR (n = 36) | Improvement of ≥ 1-point RSI and RFS: 68% | 24 wk lansoprozole (30 mg, 2/d) and diet |
Gr2: CT (n = 23) | |||||
Garrigues et al[22], 2003 | Pros Uncontr | IIIb | Suspected LPR (n = 91) | Symptom improvement/resolution: 86-41% | 24 w omeprazole (20 mg, 2/d) |
Laryngoscopic sign resolution: 83% | |||||
Beaver et al[23], 2003 | Pros Uncontr | IIIb | Suspected LPR (n = 49) | Pre to post-LPR sign score improvement: +1 | 6 wk lansoprazole (30 mg, 2/d) or pantoprazole (40 mg, 2/d) or Omeprazole/Rabeprazole (20 mg, 2/d) |
Siupsinskiene et al[24], 2003 | Pros Contr | IIb | Gr1: suspected LPR (n = 113) | Symptom improvement of Gr1: 65% | Gr1-2: 5 wk omeprazole (20 mg, 1-2/d) and diet |
Gr2: healthy (n = 113) | |||||
Williams et al[25], 2004 | Pros Uncontr | IIIb | Suspected LPR (n = 20) | Improvement of ≥ 1-point level LGS: 63% | 12 wk omeprazole (20 mg, 3/d) and diet |
Improvement of symptom score: 40%-45% | |||||
Issing et al[26], 2004 | Pros Uncontr | IIIb | Suspected LPR (n = 22) | Improvement of symptom score: + | 8 wk esomeprazole (20 mg, 2/d) |
Sereg-Bahar et al[27], 2005 | Pros Uncontr | IIIb | Suspected LPR (n = 43) | Pre to post-RFS improvement: +1 | 8 wk esomeprazole (40 mg/d) and diet |
Park et al[28], 2005 | Pros Contr | IIb | Gr1: suspected LPR (n = 30) | Symptom improvement (Gr1-2):68%-46% | Gr1: 16 wk lansoprazole (30 mg, 2/d) and diet |
Gr2: suspected (n = 30) | Sign improvement (Gr1-2): 50%-18% | Gr2: Omeprazole (20 mg, 2/d) and ranitidine (300 mg/d) and diet | |||
Gr3: suspected (n = 25) | Gr3: esomeprazole (40 mg, 1/d) and diet | ||||
Vaezi et al[29], 2006 | Placebo RCT | Ib | Gr1: suspected LPR (n = 95) | Symptom resolution: 15% | Gr1-2: 16 wk placebo/esomeprazole (40 mg, 2/d) |
Gr2: suspected LPR (n = 50) | |||||
Dore et al[30], 2007 | Pros Uncontr | IIIb | Suspected LPR (n = 266) | Symptom improvement/resolution: 68%-12% | 12 wk rabeprazole/pantoprazole (20 mg, 2/d), and diet or esomeprazole (20 mg, 2/d) or lanzoprazole (30 mg, 2/d), |
Qua et al[31], 2007 | Pros Contr | IIIb | Suspected LPR (n = 32) | Gr1-2: Symptom improvement: 67%-18% | 8 wk lanzoprazole (30 mg, 2/d) |
Gr1: GERD (n = 21) | Gr1-2: LGS improvement: 86%-36% | ||||
Gr2: non-GERD (n = 11) | |||||
Oridate et al[32], 2008 | Pros Uncontr | IIIb | Suspected LPR (n = 52) | > 50% improvement of RSI and GERD: 50%-78% | 9 wk rabeprazole (20 mg/d) |
Pre to post-improvement of DLS: + | |||||
Reichel et al[33], 2008 | Placebo RCT | Ib | Gr1: suspected LPR (n = 30) | RSI improvement: 78% | Gr1-2: 12 wk placebo/esomeprazole (20 mg, 2/d) |
Gr2: suspected LPR (n = 28) | |||||
McGlashan et al[34], 2009 | Placebo RCT | Ib | Gr1: suspected LPR (n = 24) | Pre to post-RSI improvement | Gr1-2: 24 wk placebo/gaviscon (4/d) and diet |
Gr2: suspected LPR (n = 25) | |||||
Vashani et al[35], 2010 | Placebo RCT | Ib | Gr1: suspected LPR (n = 16) | Pre to post-RSI improvement: + | Gr1: 6 wk voice therapy + Omeprazole (20 mg, 2/d) |
Gr2: suspected LPR (n = 16) | Gr 2: Placebo (2/d) | ||||
Fass et al[36], 2010 | Placebo RCT | Ib | Gr1: suspected LPR (n = 24) | Pre to post-symptom improvement: + | Gr1-2: 12 wk placebo/esomeprazole (20 mg, 2/d) and diet |
Gr1: suspected LPR (n = 17) | Pre to post-RFS improvement: - | ||||
Lam et al[37], 2010 | Placebo RCT | Ib | Gr1: suspected LPR (n = 42) | Pre to post-RSI and RFS improvement: + | Gr1-2: 18 wk placebo/rabeprazole (20 mg, 2/d) and diet |
Gr2: suspected LPR (n = 40) | |||||
Ezzat et al[38], 2011 | Placebo RCT | Ib | Gr1: suspected LPR (n = 42) | RFS improvement (Gr1-2): 48%-20% | Gr1-2: 8 wk pantoprazole (40 mg/d) and itopride (50 mg, 3/d) |
Gr2: suspected LPR (n = 45) | Pre to post-symptom improvement: + | /Pantoprazole and placebo and diet | |||
Chiba et al[39], 2011 | Pros Uncontr | IIIb | Suspected LPR (n = 27) | Pre to post-GERD Score improvement: + | 8 wk lanzoprazole (30 mg/d) or rabeprazole (10 mg/d) |
Friedman et al[40], 2011 | Retrospective | IV | Gr1: LPR (n = 73) | Improvement of main complaint Gr1-2: 49%-41% | 24 wk PPI (20 or 40 mg, 2/d) |
Gr2: suspected LPR (n = 70) | Resolution of main complaint Gr 1-2: 14%-3% | ||||
Lee et al[41], 2011 | Pros Uncontr | IIIb | Suspected LPR (n = 455) | Reduction of > 50% of RSI: 75% | 12 wk rabeprazole (10/20 mg/d) and diet |
Masaany et al[42], 2011 | Pros Uncontr | IIIb | Suspected LPR (n = 47) | Reduction of ≥ 10-point of RSI: 79% | 16 wk pantoprazole (40 mg, 2/d) |
Naiboglu et al[43], 2011 | Pros Uncontr | IIIb | Suspected LPR (n = 50) | Pre to post-RSI and RFS improvement: + | 12 wk lansoprazole (30 mg/d) and diet |
Patigaroo et al[44], 2011 | Pros Uncontr | IIIb | Suspected LPR (n = 50) | Pre to post-RSI and RFS improvement: + | 16 wk esomeprazole (20 mg, 2/d)/pantoprazole (40 mg/d) |
Lansoprazole (30 mg, 2/d) | |||||
Habermann et al[45], 2012 | Pros Uncontr | IIIb | Suspected LPR (n = 1044) | Pre to post-RSI and RFS improvement: + | 12 wk pantoprazole (20 or 40 mg, 2/d) |
Park et al[46], 2012 | Pros Contro | IIIb | Gr1: suspected LPR (n = 50) | Reduction of ≥ 5-point of RSI Gr1-2:46-68% | Gr1: 12 wk omeprazole (20 mg, 2/d) |
Gr2: suspected LPR (n = 50) | Reduction of ≥ 3-point of RFS Gr1-2:18-50% | Gr2: Omeprazole + voice therapy | |||
Becker et al[47], 2012 | Pros Uncontr | IIIb | Suspected LPR (n = 30) | Reduction of RSI: 20% | 12 wk pantoprazole (40 mg, 2/d) |
Hunchaisri et al[48], 2012 | Pros Contro | IIb | Gr1: suspected LPR (n = 32) | RSI reduction: 73% | Gr1: 12 wk domperidone (10mg, 3/d) and omeprazole (20 mg, 2/d) and diet |
Gr2: suspected LPR (n = 33) | > 50% of RSI reduction: 67% | Gr2: Omeprazole (20 mg, 2/d) and diet | |||
Chung et al[49], 2012 | Pros Contro | IIb | Gr1: suspected LPR (n = 22) | Pre to post-RSI and RFS improvement: + | Gr1: 8 wk Lanzoprazole (30 mg/d) |
Gr2: suspected LPR (n = 20) | Gr2: Lanzoprazole + SGB | ||||
Oridate et al[50], 2012 | Pros Contro | IIb | Gr1: suspected LPR (n = 60) | Pre to post-RFS improvement: - | Gr 1: 4 wk rabeprazole (10 mg/d) |
Gr2: suspected LPR (N=13) | Gr 2: No treatment | ||||
Chun et al[51], 2013 | Pros Contro | IIb | Gr1: suspected LPR (n = 32) | Pre to post-RSI and RFS improvement: + | Gr1: 12 wk lanzoprazole (30 mg/d) |
Gr2: suspected LPR (n = 29) | Gr2: Lanzoprazole and itopride (50 mg 3/d) | ||||
Beech et al[52], 2013 | Pros Uncontr | IIIb | Suspected LPR (n = 74) | Reduction of ≥ 1-point of RSI: 71% | 24 wk lansoprazole (30 mg 2/d) and diet |
Improvement of pre to post-VSS: + | |||||
Vailati et al[53], 2013 | Pros Uncontr | IIIb | Suspected LPR (n = 22) | Reduction of ≥1-point of RSI: 59% | 12 wk pantoprazole (40 mg, 2/d) |
Lee et al[54], 2014 | Pros Uncontr | IIIb | Suspected LPR (n = 180) | Pre to post-RSI and RFS improvement: + | 12 wk lansoprazole (15 mg, 2/d) and diet |
Chappity et al[55], 2014 | RCT | IIb | Gr1: suspected LPR (n = 117) | Pre to post-score improvement: + | Gr1: 12 wk omeprazole (20 mg, 2/d) and diet |
Gr2: suspected LPR (n = 117) | Gr2: Diet | ||||
Wan et al[56], 2014 | Pros Contro | IIb | Gr1: suspected LPR (n = 35) | Pre to post-RSI and RFS improvement: + | 4 wk esomeprazole (20 mg, 2/d) and diet |
Gr2: LPR (n = 23) | |||||
Semmanaselvan et al[57], 2015 | Pros Uncontr | IIIb | Suspected LPR (n = 50) | Reduction of ≥ 1-point of RSI/RFS: 87%-98% | 12 wk rabeprazole (20 mg/d) and domperidone (30 mg/d) |
Ozturan et al[58], 2016 | Pros Contro | IIb | Gr1: suspected LPR (n = 65) | Pre to post-RSI and RFS improvement: + | 8 wk esomeprazole, (20 mg, 2/d) and diet |
Gr2: Control (n = 35) | |||||
Gupta et al[59], 2016 | Retrospective | IV | Suspected LPR (n = 188) | Pre to post-RSI and RFS improvement: + | 10 wk PPIs (2/d) |
Nennstiel et al[60], 2016 | Retrospective | IV | Gr1: LPR (n = 21) | Symptom VAS improvement: 60% | 12 wk pantoprazole (40 mg, 2/d) and diet |
Cross-sectional | Gr2: suspected LPR (n = 24) | ||||
Batıoğlu-Karaaltın et al[61], 2016 | Pros Uncontr | IIIb | Suspected LPR (n = 84) | Reduction of ≥ 1-point of RSI/RFS: 21%-56% | 12 wk lansoprazole (30 mg, 2/d) |
Dulery et al[62], 2016 | Pros Uncontr | IIIb | Suspected LPR (n = 24) | Symptom resolution: 10% | 8 wk esomeprazole (40 mg, 2/d) |
Joshi et al[63], 2017 | Pros Uncontr | IIIb | Suspected LPR (n = 100) | Pre to post-RSI and RFS improvement: + | 24 wk omeprazole (20 mg, 2/d) and diet |
Pullarat et al[64], 2017 | Pros Uncontr | IIIb | Suspected LPR (n = 30) | Pre to post-RSI and RFS improvement: + | 8 wk pantoprazole (40 mg/d) |
Zalvan et al[65], 2017 | Retrospective | IV | Gr1: suspected LPR (n = 85) | Reduction of ≥ 6-points of RSI Gr1-2: 54-63% | Gr1: 6 wk PPI (1 or 2/d) and diet |
Gr2: suspected LPR (n = 99) | Gr2: Diet | ||||
Carroll et al[66], 2017 | Retrospective | IV | Suspected LPR (n = 97) | RSI < 13: 49% | 12 wk omeprazole (40 mg/d) and ranitidine (300 mg/d) |
Lechien et al[67], 2018 | Pros Uncontr | IIIb | Suspected LPR (n = 80) | Post-therapy RSI < 13 and RFS < 7: 74% | 12 wk pantoprazole (20 mg, 2/d) and diet |
Mozzanica et al[68], 2018 | Pros Uncontr | IIIb | Suspected LPR (n = 34) | Pre to post-RSI, RFS, VoiSS improvement: + | 8 wk omeprazole (20 mg, 2/d) and diet |
Wilkie et al[69], 2018 | Pros Contro | IIb | Gr1: suspected LPR (n = 39) | Reduction of RSI: 94% | Gr1: 12 wk gaviscon advance (4/d) and diet |
Gr2: suspected LPR (n = 33) | Pre to post-RSI improvement: - | Gr2: Gaviscon (4/d) and PPI (NA) and diet | |||
Yang et al[70], 2018 | Retrospective | IV | Suspected LPR (n = 105) | Reduction of ≥ 1-point of RSI: 91% | 8 wk PPI (40 mg/d) ± H2 blocker (300 mg/d) and diet |
Kirti et al[71], 2018 | Pros Uncontr | IIIb | Suspected LPR (n = 80) | Unblinded RFS < 7: 95% | 8 wk PPI (2/d) and diet |
Suzuki et al[72], 2019 | Pros Contro | IIb | Gr1: suspected LPR (n = 20) | Pre to post-RSI, RFS improvement: + | Gr1: 8 wk esomeprazole (20 mg/d) |
Gr2: suspected LPR (n = 20) | Gr2: 8 wk famotidine (20 mg/d) |
Table 2 Studies that identified LPRD with objective diagnostic tools
Ref. | Design | EL | Characteristics | Outcomes | Treatment |
Noordzij et al[73], 2001 | Placebo RCT | Ib | Gr1: LPR (n = 15); Gr2: LPR (n = 15) | Pre to post-symptom improvement: +; Pre to post-sign improvement: - | Gr1-2: 8 wk placebo/omeprazole (40 mg, 2/d) |
Belafsky et al[74], 2001 | Pros Uncontr | IIIb | LPR (n = 39) | Pre to post-RSI and RFS improvement: + | 24 wk omeprazole/rabeprazole (20 mg, 2/d) or lansoprazole (30 mg, 2/d) and diet |
Belafsky et al[75], 2002 | Pros Uncontr | IIIb | LPR (n = 25) | Pre to post-RSI improvement: + | 26 wk PPIs (2/d) and diet |
Eherer et al[76], 2003 | Placebo RCT | Ib | Gr1: LPR (n = 7); Gr2: LPR (n = 7) | Symptom/sign improvement: 80%-100% | Gr1-2: 12 wk placebo/pantoprazole (40 mg, 2/d) |
Steward et al[77], 2004 | Placebo RCT | Ib | Gr1: LPR (n = 21); Gr2: LPR (n = 21) | Symptom improvement: 53% | Gr1-2: 8 wk placebo/rabeprazole (20 mg 2/d) and diet |
Wo et al[78], 2006 | Placebo RCT | Ib | Gr1: LPR (n = 19); Gr2: LPR (n = 20) | Symptom improvement: 40% | Gr1-2: 12 wk placebo/pantoprazole (40 mg/d) |
Jin et al[79], 2008 | Pros Uncontr | IIIb | LPR (n = 40) | Pre to post-RSI and RFS improvement: + | 20 wk lansoprazole (30 mg/d) and mosapride (5 mg, 3/d) or levosulpride (25 mg, 3/d) |
Friedman et al[40], 2011 | Retrospective | IV | Gr1: LPR (n = 73); Gr2: suspected LPR (n = 70) | Improvement of main complaint Gr1-2: 49%-41%; Resolution of main complaint Gr 1-2: 14%-3% | 24 wk PPI (20 or 40 mg, 2/d) and diet |
Lien et al[80], 2013 | Pros Contr | IIIb | Gr1: GERD and LPR (n = 65); Gr2: LPR (n = 42) | Reduction of > 50% of RSI (Gr1-2): 63%-17% | 12 wk esomeprazole (40 mg, 2/d) and diet |
Wan et al[56], 2014 | Pros Contr | IIb | Gr1: suspected LPR (n = 35); Gr2: LPR (n = 23) | Pre to post-RSI and RFS improvement: + | 4 wk esomeprazole (20 mg, 2/d) and diet |
Waxman et al[81], 2014 | Retrospective | IV | LPR (n = 43) | Reduction of ≥ 1-point of RSI: 67% | 4 wk omeprazole (40 mg, 2/d) |
Nennstiel et al[60], 2016 | Retrospective | IV | Gr1: LPR (n = 21); Gr2: suspected LPR (n = 24) | Symptom VAS improvement: 60% | 12 wk pantoprazole (40mg, 2/d) and diet |
Cross-sectional | |||||
Tseng et al[82], 2018 | Placebo RCT | Ib | Gr1: LPR (n = 39); Gr2: LPR (n = 40) | Pre to post-RSI and RFS improvement: + | Gr1-2: 8 wk alginate/placebo and diet |
Agrawal et al[83], 2018 | Pros Uncontr | IIIb | LPR (n = 33) | Reduction of > 50% of RSI: 45% | 8-12 wk omeprazole and diet |
Table 3 Proton pump inhibitor therapeutic schemes used in the current literature
Drugs and duration | Study numbers |
4-5 wk | |
Omeprazole 40mg 1/d | 1 |
Omeprazole 20mg 1/d | 3 |
Omeprazole 40mg 2/d | 1 |
Esomeprazole 20mg 2/d | 2 |
Rabeprazole 10mg 1/d | 1 |
6-7 wk | |
Pantoprazole 40mg 2/d | 1 |
Pantoprazole 40mg 1/d | 2 |
Lansoprazole 30mg 2/d | 1 |
Omeprazole 20mg 2/d | 2 |
8-9 wk | |
Omeprazole 40mg 1/d | 1 |
Omeprazole 20mg 2/d | 1 |
Omeprazole 40mg 2/d | 1 |
Esomeprazole 40mg 2/d | 1 |
Esomeprazole 40mg 1/d | 2 |
Esomeprazole 20mg 2/d | 2 |
Esomeprazole 20mg 1/d | 1 |
Lansoprazole 30mg 2/d | 1 |
Lansoprazole 30mg 1/d | 2 |
Rabeprazole 20mg 1/d | 1 |
Rabeprazole 20mg 2/d | 1 |
Rabeprazole 10mg 1/d | 1 |
Pantoprazole 40mg 1/d | 2 |
12 wk | |
Omeprazole 40mg 1/d | 1 |
Omeprazole 20mg 3/d | 1 |
Omeprazole 20mg 2/d | 4 |
Omeprazole 20mg 1/d | 1 |
Esomeprazole 20mg 2/d | 3 |
Esomeprazole 40mg 2/d | 1 |
Lansoprazole 30mg 2/d | 4 |
Lansoprazole 15mg 2/d | 1 |
Rabeprazole 20mg 2/d | 1 |
Rabeprazole 10mg 1/d | 1 |
Pantoprazole 20 mg 2/d | 3 |
Pantoprazole 40 mg 1/d | 1 |
Pantoprazole 40 mg 2/d | 6 |
16-20 wk | |
Lansoprazole 30 mg 2/d | 2 |
Esomeprazole 40 mg 2/d | 1 |
Esomeprazole 40 mg 1/d | 1 |
Esomeprazole 20 mg 2/d | 1 |
Rabeprazole 20 mg 2/d | 1 |
Pantoprazole 40 mg 2/d | 1 |
Pantoprazole 40 mg 1/d | 1 |
24 wk | |
Omeprazole 20 mg 2/d | 2 |
Omeprazole 20 mg 1/d | 1 |
Lansoprazole 30 mg 2/d | 3 |
Table 4 Composite treatments used in the current literature
Drugs and duration | Study numbers |
PPIs and antihistamines | |
Omeprazole 20 mg 2/d and Ranitidine 300 mg/d (16 wk) | 1 |
Omeprazole 40 mg/d and Ranitidine 300 mg/d (12 wk) | 1 |
PPIs 40 mg/d and antihistamine 300 mg/d (8 wk) | 1 |
PPIs and gastroprokinetic | |
Pantoprazole 40 mg 2/d and Cisapride 20 mg 2/d (4 wk) | 1 |
Pantoprazole 40 mg 1/d and Itopride 50 mg 3/d (8 wk) | 1 |
Omeprazole 20 mg 2/d and Domperidone 10 mg 3/d (12 wk) | 1 |
Lansoprazole 30 mg 1/d and Itopride 50 mg 3/d (12 wk) | 1 |
Rabeprazole 20 mg/d and Domperidone 30 mg/d (12 wk) | 1 |
Lansoprazole 30 mg 1/d and Mosapride 5 mg 3/d (20 wk) | 1 |
PPIs and alginate | |
PPIs (NA) and gaviscon 4/d (12 wk) | 1 |
Aligante 3-4/d (8 wk) | 1 |
Other | |
Famotidine 20 mg 1/d (8 wk) | 1 |
Gaviscon 4/d (24 wk) | 1 |
Gaviscon 4/d (12 wk) | 1 |
- Citation: Lechien JR, Mouawad F, Barillari MR, Nacci A, Khoddami SM, Enver N, Raghunandhan SK, Calvo-Henriquez C, Eun YG, Saussez S. Treatment of laryngopharyngeal reflux disease: A systematic review. World J Clin Cases 2019; 7(19): 2995-3011
- URL: https://www.wjgnet.com/2307-8960/full/v7/i19/2995.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i19.2995